Pauling.AI and Nawah Scientific Unite AI and Experimental Science in an Integrated Drug Discovery Partnership
New partnership combines autonomous in silico discovery with high-velocity wet-lab validation—giving pharmaceutical and biotechnology companies one coordinated path from target hypothesis to experimentally tested molecules.
BOSTON and CAIRO — 20th August 2026 — Pauling.AI, developer of a fully autonomous computational drug discovery platform, and Nawah Scientific, one of the Middle East and Africa’s leading scientific research and analytical platforms, today announced a strategic partnership to deliver an integrated dry-lab and wet-lab drug discovery offering to pharmaceutical and biotechnology companies worldwide.
The partnership closes one of drug discovery’s most persistent gaps: the disconnect between computational prediction and experimental proof.
Pauling.AI transforms biological targets and research hypotheses into prioritized molecular candidates through autonomous workflows spanning virtual screening, molecular docking, molecular dynamics, binding-affinity analysis, ADMET prediction and candidate ranking. Nawah Scientific then brings these computational proposals into the physical world through tailored experimental validation, including biochemical and cell-based assays, analytical characterization, early efficacy studies, pharmacokinetic investigations and other preclinical services.
Together, the companies will offer clients a unified commercial and scientific engagement—one coordinated project connecting computation, experimentation and data-driven iteration.
Closing the Discovery Loop
AI can search chemical space at a scale no traditional discovery team can match. But computational predictions remain hypotheses until they face biological reality.
Under the partnership, Pauling.AI will identify and prioritize high-potential molecules before experimental work begins. Nawah will then generate the wet-lab evidence needed to confirm activity, investigate biological performance and identify the most promising candidates for further development. Experimental findings can subsequently inform additional computational cycles, creating a faster, evidence-driven discovery loop.
This integrated approach is designed to help discovery teams:
- Screen substantially larger chemical spaces without expanding internal infrastructure.
- Focus laboratory resources on the most promising molecules.
- Reduce expenditure on low-probability candidates.
- Move rapidly between prediction, testing and molecular optimization.
- Manage the dry-lab and wet-lab phases through one coordinated engagement.
- Access flexible discovery capacity without building additional computational or laboratory teams.
“This partnership represents the drug discovery model of the future: intelligence and experimentation operating as one continuous system,” said Dr. Omar Sakr, Founder and CEO of Nawah Scientific. “Pauling.AI can explore molecular possibilities at extraordinary speed. Nawah provides the experimental power to challenge those possibilities, generate real biological evidence and determine what deserves to move forward. We are not simply connecting two service providers—we are building a faster route from scientific imagination to experimentally supported opportunity.”
“Computational discovery should not end with a ranked spreadsheet,” said Javier Tordable, CEO of Pauling.AI. “The value emerges when predictions are tested, the resulting evidence is understood and the system learns where to search next. By combining Pauling.AI’s autonomous computational platform with Nawah’s extensive wet-lab capabilities, clients can move from target to testable molecules through a single, tightly coordinated workflow.”
Built for the Next Generation of Pharma and Biotech
The joint offering is designed for pharmaceutical companies, biotechnology ventures, virtual biotech teams, academic spinouts and investor-backed drug discovery programs across Europe, the United States and other global markets.
It is particularly suited to organizations seeking to expand discovery capacity, pursue new or underexplored targets, validate AI-generated candidates, accelerate hit identification or initiate programs without making heavy upfront investments in specialized infrastructure and multidisciplinary teams.
Rather than transferring projects between disconnected computational vendors and contract laboratories, clients will gain access to an integrated team capable of coordinating molecular selection, experimental design, data generation and subsequent iteration.
The result is a more connected discovery engine: AI proposes, biology challenges, data redirects—and the cycle continues until the strongest candidates emerge.
About Pauling.AI
Pauling.AI is a Boston-based computational drug discovery company developing a fully autonomous platform for molecular discovery. Its technology integrates AI agents, physics-based computational chemistry and enterprise-scale cloud infrastructure to automate workflows including structure preparation, large-scale virtual screening, molecular docking, molecular dynamics, binding-affinity analysis, ADMET prediction and candidate prioritization.
Pauling.AI’s mission is to make sophisticated computational drug discovery faster, more accessible and immediately actionable for medicinal chemists, biotechnology companies and pharmaceutical research teams.
For more information, visit www.pauling.ai.
About Nawah Scientific
Nawah Scientific is a multidisciplinary scientific research, analytical and drug development platform serving pharmaceutical companies, biotechnology ventures, industrial organizations and researchers. Through its online-enabled operating model and advanced laboratory infrastructure, Nawah provides access to hundreds of analytical, biological and preclinical services across drug discovery, pharmaceutical development and the life sciences.
With extensive scientific expertise, internationally recognized quality systems and a multidisciplinary team of researchers, Nawah enables its clients to outsource complex experimental work through a single, coordinated scientific partner.
For more information, visit www.nawah-scientific.com.
Media Contacts
Nawah Scientific
Dr. Omar Sakr
Founder and CEO
omar.sakr@nawah-scientific.com
www.nawah-scientific.com
Pauling.AI
Media Relations
info@pauling.ai
www.pauling.ai
